The fight against cancer is a never-ending one, and Tetra Bio-Pharma Inc. (TSX-Venture:TBP) is building up the weaponry for its latest salvo.
The Ottawa-based drug maker announced Tuesday it is ready to resume its Phase 3 clinical program in advanced cancer pain patients.
The SERENITY© Study will use a vaporizer, a Health Canada-approved Class 2 medical device as a delivery mechanism which is more acceptable to hospitals and palliative care centres. Tetra’s new drug formerly referred to as PPP-001 will be investigated in the SERENITY © Study under the commercial label, CAUMZ.
According to CEO Guy Chamberland, “With great challenge comes great opportunity and what we are now able to deliver is a better and more reliable product.”
As for the company’s shares, they rocketed six cents, or 9.4%, Tuesday afternoon, to 70 cents, on volume of 911,000 shares.
